Date Title Description PDF
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 About Corporate Governance The Company informs about the agreements adopted by the Board of Directors Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download
21 Feb 2023 On business and financial situation The company releases the Integrated Report for the year 2022 Download

Pages

Date Title Description PDF
21 Oct 2021 Liquidity and counterparty agreements Download
21 Oct 2021 On business and financial situation The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). Download
07 Oct 2021 Liquidity and counterparty agreements Download
04 Oct 2021 Liquidity and counterparty agreements Download
01 Sep 2021 On business and financial situation ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine Download

Pages

Date Title Description PDF
20 Feb 2018 Información sobre resultados ROVI releases the presentation related to the full year 2017 results Download
20 Feb 2018 Información sobre resultados ROVI releases the press release related to the full year 2017 results Download
20 Feb 2018 Informe anual de remuneraciones de los consejeros ROVI releases the 2017 annual report regarding remuneration of the members of the Board of Directors Download
20 Feb 2018 Informe Anual de Gobierno Corporativo ROVI releases the 2017 Annual Corporate Governance Report Download
20 Feb 2018 Otros sobre gobierno corporativo The Company informs about the agreements adopted by the Board of Directors Download

Pages